课题基金 / 基金详情

PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS

PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS
硝唑尼特隐孢子虫病治疗艾滋病的 I/II 期开放标签评估
批准号:
6113997
负责人:
ROSEMARY SOAVE
金额:
$7.95万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

ROSEMARY SOAVE的其他基金

相似基金

相关文献

中文摘要
翻译
本研究的目的是确定nitazoxanide在艾滋病相关隐孢子虫腹泻患者中的药代动力学,评估其安全性和有效性,并确定重复给药后nitazoxanide的稳态浓度。另一个目的是评估吸收不良(由d-木糖吸收试验确定)、硝唑昔尼德血药浓度和疗效之间的关系。进展报告和研究结果总结:在此期间没有新受试者入组。最初参加I/II期研究的三名受试者在同情维持的基础上继续接受NTZ治疗,并保持改善。结果仍在分析中。
英文摘要
The objectives of this study are to determine the pharmacokinetics and assess safety and efficacy of nitazoxanide in patients with AIDS-related cryptosporidial diarrhea, and determine steady state concentrations of nitazoxanide following repeated dosing. Another objective is to assess the relationship between malabsorption, as determined by the d-xylose absorption test, nitazoxanide blood levels, and efficacy. Progress report and summary of findings: No new subjects were enrolled during this period. Three subjects originally enrolled in the Phase I/II study who continued NTZ therapy on a compassionate maintenance basis were followed and remained improved. Results continue to be analyzed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IMMUNOPATHOGENESIS OF CRYPTOSPORIDIOSIS
SAFETY & EFFICACY OF CLARITHROMYCIN FOR AIDS-RELATED CRYPTOSPORIDIAL DIARRHEA
PHASE I/II OPEN LABEL EVALUATION OF NITAZOXANIDE CRYPTOSPORIDIOSIS IN AIDS
IMMUNOPATHOGENESIS OF CRYPTOSPORIDIOSIS
国内基金
海外基金
人类和非人灵长类人隐孢子虫(Cryptosporidium hominis)的人兽共患传播机制研究
  • 批准号:
    U1404327
  • 项目类别:
    联合基金项目
  • 资助金额:
    30.0万元
  • 批准年份:
    2014
  • 负责人:
    朱惠丽
  • 依托单位: